Monitoring heart injury in cancer patients receiving immune checkpoint therapy
Official title: STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
Run by M.D. Anderson Cancer Center · NCT06337097 · Data updated 2026-11-12
This study tests if checking blood levels of a heart injury marker can help cancer patients on immune checkpoint therapy avoid heart problems and improve their treatment experience.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 980 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | February 2, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2028 |
| Registry record updated | August 10, 2026 |
| Trial ID | NCT06337097 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are planning to receive immune checkpoint inhibitors as part of their cancer treatment.
✕Probably not a fit
Patients who have had a major adverse cardiovascular event within 30 days prior to enrollment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to determine if tracking blood levels of troponin, a marker for heart injury, can help reduce heart-related side effects in cancer patients undergoing treatment with immune checkpoint inhibitors. It focuses on various cardiovascular events, including myocarditis and heart failure, and assesses the time to diagnosis and hospitalization duration for these events. The study will also evaluate the impact of troponin monitoring on cancer progression and the need for additional cardiac testing.
Why it matters
Potential benefit: If successful, this approach could lead to improved cardiovascular safety and outcomes for cancer patients receiving immune checkpoint therapy.
How similar studies have gone: While monitoring cardiac biomarkers in cancer patients is a growing area of interest, this specific approach to troponin surveillance during immune checkpoint therapy is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patient ≥18 years old * Plan for treatment with an immune checkpoint inhibitor as standard of care even if patient is also on an additional investigational cancer therapeutic * Willingness to provide informed consent Exclusion Criteria: * Troponin T not available at screening or prior to randomization * Inability to comply with planned study procedures * Major adverse cardiovascular event included in the primary outcome within the 30 days prior to enrollment * Any medical condition that could interfere with, or for which the treatment might interfere with the conduct of the study or interpretation of the study results, or that would, in the opinion of the investigator, increase the risk of the participant by participating in the study * Any factors that, in the Investigator's opinion, are likely to interfere with study procedures, such as history of noncompliance with scheduled appointments.
Where it's running
-
MD Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Nicolas Palaskas, MD — M.D. Anderson Cancer Center
- Study coordinator: Nicolas Palaskas, MD
- Email: nlpalaskas@mdanderson.org
- Phone: (713) 606-3957
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Node-sparing low-dose radiotherapy combined with chemotherapy and PD-1 blocker for high-risk pMMR/MSS locally advanced colon cancer.
This trial tests whether adding node-sparing low-dose radiotherapy to standard chemotherapy and a PD-1 blocker can improve tumor response in adults with high-risk, locally advanced pMMR/MSS colon cancer before surgery.
-
Node-sparing hypofractionated radiotherapy with chemotherapy and PD-1 blockade for high-risk MSS/pMMR locally advanced colon cancer
This trial will test whether node-sparing, short-course radiotherapy combined with chemotherapy and a PD-1 blocker can improve pre-surgery tumor response in adults with high-risk, microsatellite-stable (pMMR/MSS) locally advanced colon cancer.
-
Node-sparing radiotherapy with chemotherapy and PD-1 inhibitor for rectal cancer
This study is testing a new treatment for mid-low rectal cancer that combines special radiation, chemotherapy, and an immune booster to see if it helps patients respond better while protecting their lymph nodes.
-
Combining node-sparing radiotherapy with chemotherapy and immunotherapy for metastatic colorectal cancer
This study is testing a new treatment that combines a special type of radiation with chemotherapy and immunotherapy to see if it can help people with metastatic colorectal cancer live longer and feel better.
-
Combining long-course radiotherapy, chemotherapy, and PD-1 inhibitor for high-risk rectal cancer
This study is testing a new treatment plan that combines radiation, chemotherapy, and a PD-1 inhibitor to see if it helps people with high-risk rectal cancer do better than with standard treatments.
-
Testing a blood test to predict response to cancer immunotherapy
This study is testing a blood test to see if it can predict how well people with advanced cancer will respond to a specific type of immunotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.